
ASLAN Pharmaceuticals Limited – NASDAQ:ASLN
ASLAN Pharmaceuticals Limited stock price today
ASLAN Pharmaceuticals Limited stock price monthly change
ASLAN Pharmaceuticals Limited stock price quarterly change
ASLAN Pharmaceuticals Limited stock price yearly change
ASLAN Pharmaceuticals Limited key metrics
Market Cap | 1.69M |
Enterprise value | N/A |
P/E | -0.79 |
EV/Sales | N/A |
EV/EBITDA | 0.37 |
Price/Sales | N/A |
Price/Book | 0.35 |
PEG ratio | N/A |
EPS | -1.98 |
Revenue | N/A |
EBITDA | -30.98M |
Income | -35.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeASLAN Pharmaceuticals Limited stock price history
ASLAN Pharmaceuticals Limited stock forecast
ASLAN Pharmaceuticals Limited financial statements
Jul 2023 | 12M | -1.88M | -15.71% |
---|---|---|---|
Sep 2023 | 0 | -9.70M | |
Dec 2023 | 0 | -13.51M | |
Mar 2024 | 0 | -9.91M |
Dec 2023 | 0 | -13.51M | |
---|---|---|---|
Mar 2024 | 0 | -9.91M | |
Sep 2025 | 0 | -11.20M | |
Dec 2025 | 0 | -11.76M |
Analysts Price target
Financials & Ratios estimates
2022-08-12 | -1.50413 | -0.95 |
---|---|---|
2022-10-28 | -0.67368 | -0.8 |
2023-03-24 | -1.21524 | -1.04 |
Jul 2023 | 55205857 | 48.83M | 88.46% |
---|---|---|---|
Sep 2023 | 44635264 | 45.51M | 101.98% |
Dec 2023 | 24626525 | 37.91M | 153.95% |
Mar 2024 | 20988241 | 38.95M | 185.6% |
Dec 2022 | -6.23M | -30.21K | 9.11M |
---|---|---|---|
Mar 2023 | 0 | 0 | 0 |
Jul 2023 | 0 | 0 | 0 |
Sep 2023 | 0 | 0 | 0 |
ASLAN Pharmaceuticals Limited alternative data
Aug 2023 | 34 |
---|---|
Sep 2023 | 34 |
Oct 2023 | 34 |
Nov 2023 | 34 |
Dec 2023 | 34 |
Jan 2024 | 34 |
Feb 2024 | 34 |
Mar 2024 | 34 |
Apr 2024 | 34 |
May 2024 | 35 |
Jun 2024 | 35 |
Jul 2024 | 35 |
ASLAN Pharmaceuticals Limited other data
-
What's the price of ASLAN Pharmaceuticals Limited stock today?
One share of ASLAN Pharmaceuticals Limited stock can currently be purchased for approximately $0.56.
-
When is ASLAN Pharmaceuticals Limited's next earnings date?
Unfortunately, ASLAN Pharmaceuticals Limited's (ASLN) next earnings date is currently unknown.
-
Does ASLAN Pharmaceuticals Limited pay dividends?
No, ASLAN Pharmaceuticals Limited does not pay dividends.
-
How much money does ASLAN Pharmaceuticals Limited make?
ASLAN Pharmaceuticals Limited has a market capitalization of 1.69M. ASLAN Pharmaceuticals Limited made a loss 44.22M US dollars in net income (profit) last year or -$1.04 on an earnings per share basis.
-
What is ASLAN Pharmaceuticals Limited's stock symbol?
ASLAN Pharmaceuticals Limited is traded on the NASDAQ under the ticker symbol "ASLN".
-
What is ASLAN Pharmaceuticals Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ASLAN Pharmaceuticals Limited?
Shares of ASLAN Pharmaceuticals Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does ASLAN Pharmaceuticals Limited have?
As Jul 2024, ASLAN Pharmaceuticals Limited employs 35 workers, which is 3% more then previous quarter.
-
When ASLAN Pharmaceuticals Limited went public?
ASLAN Pharmaceuticals Limited is publicly traded company for more then 7 years since IPO on 4 May 2018.
-
What is ASLAN Pharmaceuticals Limited's official website?
The official website for ASLAN Pharmaceuticals Limited is aslanpharma.com.
-
How can i contact ASLAN Pharmaceuticals Limited?
ASLAN Pharmaceuticals Limited can be reached via phone at +65 6222 4235.
ASLAN Pharmaceuticals Limited company profile:

ASLAN Pharmaceuticals Limited
aslanpharma.comNASDAQ
35
Biotechnology
Healthcare
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Singapore, 239920
CIK: 0001722926
ISIN: US04522R2004
CUSIP: 04522R101